EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
复制标题
DOI：
10.1007/s00125-016-3902-y
复制
发表时间：
2016-06-01
期刊：
影响因子：
8.2
通讯作者：
中科院分区：
文献类型：
--
作者：
临床实践指南（CPG）为非酒精性脂肪肝（NAFLD）患者的诊断，治疗和随访提出了建议，是欧洲肝脏研究协会（EASL），欧洲糖尿病研究协会（EASD）和欧洲肥胖研究协会（EASO）共同努力的产物。他们更新了基于2009年EASL特别会议的立场声明[1]。数据已通过广泛的PubMed检索检索到2015年4月。最终陈述根据证据等级和建议强度进行分级，可根据当地法规和/或团队能力进行调整（表1）[2]。特别是，在风险人群中筛查NAFLD应在可用资源的背景下进行，考虑到国家医疗保健系统的负担和目前有限的有效治疗。该文件旨在实际使用和促进成人NAFLD的研究和知识，并在必要时特别提到儿科NAFLD。最终目的是改善患者护理和对NAFLD重要性的认识，并通过提供基于证据的数据来协助利益相关者进行决策，同时考虑到医疗保健系统的临床管理负担。
The Clinical Practice Guidelines (CPG) propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). They update a position statement based on the 2009 EASL Special Conference [1].The data have been retrieved by an extensive PubMed search up to April 2015. The final statements are graded according to the level of evidence and strength of recommendation, which are adjustable to local regulations and/or team capacities (table 1)[2]. In particular, screening for NAFLD in the population at risk should be in the context of the available resources, considering the burden for the national healthcare systems and the currently limited effective treatments. The document is intended both for practical use and for advancing the research and knowledge of NAFLD in adults, with specific reference to paediatric NAFLD, whenever necessary. The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.